Rxsight (RXST) Osake Kurssi
Rxsight Kurssi
Viimeisten 6 vuoden aikana Rxsightn liikevaihto kasvoi 97,9 % vuodessa ja ylsi 134,48 M USD:een. Rxsightn nettomarginaali −29,0 % on noussut verrattuna −215,5 %:iin muutama vuosi sitten. Rxsightn 12 kuukauden konsensustavoitehinta on 6,75 USD, noin yli kurssia 40,6 %. 15 analyytikosta 1 suosittaa ostoa — kokonaiskonsensus on Pidä.
Rxsight osakekurssi
Rxsight liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Rxsight -osakkeesta
The business model of Rxsight Inc revolves around providing innovative and personalized solutions in the field of ophthalmic surgery. Rxsight offers an adjustable intraocular lens (IOL) system known as RxSight Light Adjustable Lens (LAL). This advanced technology allows eye surgeons to make post-surgical adjustments to patients' lens power, improving visual outcomes. With a focus on precision and patient satisfaction, Rxsight aims to revolutionize cataract and refractive surgeries. By utilizing cutting-edge light-based technology, Rxsight Inc aims to enhance the quality of vision correction procedures and provide tailored solutions for individuals seeking the best possible visual outcomes.
Rxsight Inc is primarily active in the healthcare and medical technology industries.
The main competitors of Rxsight Inc in the market are other companies operating in the ophthalmology industry, such as Johnson & Johnson Vision, Novartis AG, Bausch Health Companies Inc., and Carl Zeiss Meditec AG. These companies also provide innovative and advanced solutions in the field of vision correction and ocular devices. Rxsight Inc faces competition from these established players as they all strive to provide effective and reliable products to enhance visual outcomes and improve patient satisfaction.
Rxsight Inc is a renowned medical technology company specializing in advanced adjustable intraocular lens (IOL) systems. Founded in [year], Rxsight has established itself as a leader in the field of ophthalmology and vision correction. The company's innovative IOLs provide patients with improved vision post-cataract surgery, allowing for precise and personalized adjustments to address individual visual needs. Rxsight's dedication to research and development has led to groundbreaking solutions for vision enhancement, ensuring optimal outcomes for patients worldwide. With a strong commitment to innovation and patient care, Rxsight Inc continues to revolutionize the way we approach vision correction surgeries.
Rxsight Inc has accomplished several significant milestones in its history. One notable achievement was the FDA approval of its customizable intraocular lens (IOL) in 2017. This breakthrough technology allows ophthalmologists to provide patients with a highly precise vision correction solution tailored to their specific needs. Rxsight Inc also successfully raised $50 million in a recent funding round, which will support further research and development efforts. Additionally, the company has expanded its global presence, forging strategic partnerships with leading healthcare organizations. These achievements highlight Rxsight Inc's commitment to revolutionizing vision care and solidify its position as a pioneer in the field.
Rxsight Inc is primarily present in the United States.
Rxsight Inc represents a strong commitment to innovation and improving people's lives. With a focus on precision medicine, Rxsight develops and provides advanced customizable intraocular lens technology for cataract surgery. The company's corporate philosophy revolves around ensuring exceptional vision outcomes for patients and optimizing surgeon workflow. Rxsight embraces collaboration with medical professionals and is dedicated to enhancing surgical techniques through technological advancements. By continually pushing boundaries and delivering personalized solutions, Rxsight aims to empower both patients and healthcare providers in achieving the best possible visual results.
Analyytikot asettavat tällä hetkellä Rxsight-osakkeelle keskimääräisen tavoitehinnan 7,50 USD (mediaani: 6,75 USD), mikä merkitsee +56,2 % viimeisimpään hintaan verrattuna. Konsensus perustuu 15 analyytikkoarvioon.
15 analyytikkoa arvioi tällä hetkellä Rxsight-osaketta: 1 suosittaa ostoa, 9 pitoa ja 5 myyntiä. Vuodelle 2026 analyytikot odottavat Rxsight-yhtiöltä 147,03 M USD liikevaihtoa ja −0,94 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Rxsight-osake noteerataan hintaan 4,29 EUR (4,80 USD).
Rxsight-osake (RXST) on listattuna 1 pörssissä, muun muassa: NASDAQ (RXST).
Rxsight Inc. is a company that specializes in the development of innovative optical systems. The company offers a variety of products and services ranging from vision correction to vision optimization. One of Rxsight's main areas is the development of custom contactless intraocular lenses. The company uses a patented technology called Light Adjustable Lens (LAL) to perform lens correction that provides personalized and precise adjustment. With this technology, doctors can adjust the lenses after surgery and optimize the patient's vision. Rxsight also offers specialized devices and instruments for eye surgery, including the Light Delivery System. This system allows for the adjustment and optimization of corrected vision in the operating room. Additionally, the company provides software that allows doctors to manage and control the exact parameters and settings. In addition to intraocular lenses and related equipment, Rxsight also specializes in custom eyeglass lenses. With their patented technology called Cerium Lens, they create custom or tailored glasses that are more precisely adapted to individual needs. These eyeglass lenses offer improved vision quality in all lighting conditions. Another important area of Rxsight is their remote treatment program. Under the brand TeleOPTIC, they offer a platform that enables remote diagnosis and treatment for patients who are unable to come to an eye clinic in person. Through this technology, eye doctors can remotely care for patients with a variety of eye problems and provide remote support and assistance. Rxsight's business model is focused on processing and integrating data and technologies. Collaboration with doctors and eye innovators is at the core of their efforts. The company is dedicated to improving vision quality and offers innovative products and services to achieve this vision. In conclusion, Rxsight Inc. is an important company in the field of optometry. The company's patented technology, Light Adjustable Lens, allows doctors to precisely adjust patients' corrected vision. Additionally, Rxsight also offers eyeglass lenses and remote treatment programs. Through the integration of data and technologies, the company aims to improve vision quality and meet the needs of patients and eye doctors.
odotettu liikevaihto Rxsight on 147,03 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Rxsight on −38,59 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Rxsight:n hinta-voitto-suhde (P/E) on tällä hetkellä −5,12. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Rxsight-osakkeen arvostusta.
Rxsight:n hinta-myynti-suhde (P/S) on tällä hetkellä 1,34. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Rxsight-osakkeen arvostuskennuslukuna.
Rxsight:n Eulpool-laatuscore on 3/10.
Rxsight:n ISIN on US78349D1072. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Rxsight:n ticker on RXST. Tämä pörssinoteeraus käytetään Rxsight-osakkeiden kauppaan pörssissä.
Rxsight osake
Rxsight vertaisryhmä
Rxsight Ticker
Rxsight FIGI
Kaikki tunnusluvut ja syvällinen analyysi Rxsight:sta
Meidän osakeanalyysimme Rxsight-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Rxsight:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: